Overview

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

Status:
Completed
Trial end date:
2016-06-08
Target enrollment:
Participant gender:
Summary
Patients who have not had adequate blood count recovery post related or unrelated stem cell transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully improve their blood counts.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
JM 3100
Lenograstim
Plerixafor